ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries -- Dublin-based subsidiary to support ImmunityBio's distribution and ...
Stocktwits on MSN
IBRX stock surges past 4-year highs: Analyst sees over 50% upside after Anktiva’s blowout growth
H.C. Wainwright raised its price target to $15 from $10, reiterating a 'Buy' rating and implying over 50% upside from current levels. ・Anktiva's full-year net product revenue hit $113 million in 2025, ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most respected healthcare commercial and ...
ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early ...
Protara Therapeutics (NASDAQ:TARA) on February 23, 2026, announced updated interim data from its ongoing Phase 2 ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle ...
ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year ...
Hundreds of people in England with aggressive bladder cancer are set to benefit from a new dual‑stage immunotherapy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results